These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
376 related articles for article (PubMed ID: 34440646)
1. The Combined Treatment with Chemotherapeutic Agents and the Dualsteric Muscarinic Agonist Iper-8-Naphthalimide Affects Drug Resistance in Glioblastoma Stem Cells. Guerriero C; Matera C; Del Bufalo D; De Amici M; Conti L; Dallanoce C; Tata AM Cells; 2021 Jul; 10(8):. PubMed ID: 34440646 [TBL] [Abstract][Full Text] [Related]
2. Activation of M2 muscarinic acetylcholine receptors by a hybrid agonist enhances cytotoxic effects in GB7 glioblastoma cancer stem cells. Cristofaro I; Spinello Z; Matera C; Fiore M; Conti L; De Amici M; Dallanoce C; Tata AM Neurochem Int; 2018 Sep; 118():52-60. PubMed ID: 29702145 [TBL] [Abstract][Full Text] [Related]
3. The Combination of the M2 Muscarinic Receptor Agonist and Chemotherapy Affects Drug Resistance in Neuroblastoma Cells. Lucianò AM; Perciballi E; Fiore M; Del Bufalo D; Tata AM Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33182656 [TBL] [Abstract][Full Text] [Related]
4. Glioblastoma stem cells deliver ABCB4 transcribed by ATF3 via exosomes conferring glioblastoma resistance to temozolomide. Xu X; Zheng Y; Luo L; You Z; Chen H; Wang J; Zhang F; Liu Y; Ke Y Cell Death Dis; 2024 May; 15(5):318. PubMed ID: 38710703 [TBL] [Abstract][Full Text] [Related]
5. Cross Interaction between M2 Muscarinic Receptor and Notch1/EGFR Pathway in Human Glioblastoma Cancer Stem Cells: Effects on Cell Cycle Progression and Survival. Cristofaro I; Alessandrini F; Spinello Z; Guerriero C; Fiore M; Caffarelli E; Laneve P; Dini L; Conti L; Tata AM Cells; 2020 Mar; 9(3):. PubMed ID: 32182759 [TBL] [Abstract][Full Text] [Related]
6. Cell surface vimentin-targeted monoclonal antibody 86C increases sensitivity to temozolomide in glioma stem cells. Noh H; Zhao Q; Yan J; Kong LY; Gabrusiewicz K; Hong S; Xia X; Heimberger AB; Li S Cancer Lett; 2018 Oct; 433():176-185. PubMed ID: 29991446 [TBL] [Abstract][Full Text] [Related]
7. Combined PDK1 and CHK1 inhibition is required to kill glioblastoma stem-like cells in vitro and in vivo. Signore M; Pelacchi F; di Martino S; Runci D; Biffoni M; Giannetti S; Morgante L; De Majo M; Petricoin EF; Stancato L; Larocca LM; De Maria R; Pallini R; Ricci-Vitiani L Cell Death Dis; 2014 May; 5(5):e1223. PubMed ID: 24810059 [TBL] [Abstract][Full Text] [Related]
8. M2 Receptor Activation Counteracts the Glioblastoma Cancer Stem Cell Response to Hypoxia Condition. Cristofaro I; Limongi C; Piscopo P; Crestini A; Guerriero C; Fiore M; Conti L; Confaloni A; Tata AM Int J Mol Sci; 2020 Mar; 21(5):. PubMed ID: 32131421 [TBL] [Abstract][Full Text] [Related]
9. The efficacy of a coordinated pharmacological blockade in glioblastoma stem cells with nine repurposed drugs using the CUSP9 strategy. Skaga E; Skaga IØ; Grieg Z; Sandberg CJ; Langmoen IA; Vik-Mo EO J Cancer Res Clin Oncol; 2019 Jun; 145(6):1495-1507. PubMed ID: 31028540 [TBL] [Abstract][Full Text] [Related]
13. The activation of M2 muscarinic receptor inhibits cell growth and survival in human glioblastoma cancer stem cells. Alessandrini F; Cristofaro I; Di Bari M; Zasso J; Conti L; Tata AM Int Immunopharmacol; 2015 Nov; 29(1):105-9. PubMed ID: 26033491 [TBL] [Abstract][Full Text] [Related]
14. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells. Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502 [TBL] [Abstract][Full Text] [Related]
15. Combined expressional analysis, bioinformatics and targeted proteomics identify new potential therapeutic targets in glioblastoma stem cells. Stangeland B; Mughal AA; Grieg Z; Sandberg CJ; Joel M; Nygård S; Meling T; Murrell W; Vik Mo EO; Langmoen IA Oncotarget; 2015 Sep; 6(28):26192-215. PubMed ID: 26295306 [TBL] [Abstract][Full Text] [Related]
16. The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma. Banelli B; Carra E; Barbieri F; Würth R; Parodi F; Pattarozzi A; Carosio R; Forlani A; Allemanni G; Marubbi D; Florio T; Daga A; Romani M Cell Cycle; 2015; 14(21):3418-29. PubMed ID: 26566863 [TBL] [Abstract][Full Text] [Related]
17. Extracellular vesicles derived from hypoxic glioma stem-like cells confer temozolomide resistance on glioblastoma by delivering miR-30b-3p. Yin J; Ge X; Shi Z; Yu C; Lu C; Wei Y; Zeng A; Wang X; Yan W; Zhang J; You Y Theranostics; 2021; 11(4):1763-1779. PubMed ID: 33408780 [No Abstract] [Full Text] [Related]
18. Modulating lncRNA SNHG15/CDK6/miR-627 circuit by palbociclib, overcomes temozolomide resistance and reduces M2-polarization of glioma associated microglia in glioblastoma multiforme. Li Z; Zhang J; Zheng H; Li C; Xiong J; Wang W; Bao H; Jin H; Liang P J Exp Clin Cancer Res; 2019 Aug; 38(1):380. PubMed ID: 31462285 [TBL] [Abstract][Full Text] [Related]
19. TRPML2 Mucolipin Channels Drive the Response of Glioma Stem Cells to Temozolomide and Affect the Overall Survival in Glioblastoma Patients. Morelli MB; Nabissi M; Amantini C; Maggi F; Ricci-Vitiani L; Pallini R; Santoni G Int J Mol Sci; 2022 Dec; 23(23):. PubMed ID: 36499683 [TBL] [Abstract][Full Text] [Related]